



REGULATED INFORMATION
AUGUST 24, 2012

TiGenix receives transparency notification

Leuven (Belgium) – August 24, 2012 – TiGenix NV (NYSE Euronext Brussels: TIG) announced today that it has received a notification pursuant to the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns a notification by EFG International AG and Biopartners Capital SLU regarding the crossing below the lowest threshold of 3% by Biopartners Capital SLU (which previously held 3.25% of the TiGenix shares) on 28 July 2012.

Background: on 28 July 2012, a disinvestment agreement was entered into by and between Biopartners Capital and its investors. It was agreed that repayment of the investment was to be done in kind with TiGenix shares. By virtue of the disinvestment agreement, Biopartners Capital has transferred, effective as of 10 August 2012, its shareholding in TiGenix to its investor as re-payment of the investment.

Biopartners Capital SLU is controlled by Asesores y Gestores Financieros Private Equity SL, which in turn is controlled by Asesores y Gestores Financieros SA, which in turn is controlled by EFG International AG (a public corporation listed and traded in the SIX Swiss Exchange). This chain of control came into existence on 28 July 2012, when Asesores y Gestores Financieros Private Equity SL, in the framework of the above-mentioned disinvestment transaction, purchased all the shares in Biopartners Capital from the former Biopartners Capital shareholders. Prior to 28 July 2012, Biopartners Capital SLU was not controlled.

For further details regarding this notification, we refer to our website: <http://www.tigenix.com/en/page/26/shareholders>, where the notification has been published.

For more information:

Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com

Hans Herklots
Director Investor & Media Relations
hans.herklots@tigenix.com
+32 16 39 60 97



About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with one marketed product for cartilage repair, ChondroCelect[®], and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.